Drug Abuse: Meth’s Pollution Epidemic

Methamphetamine problems are soaring nationwide. Nearly 60% of county officials report that meth is the largest drug problem in their county, and 87% saw jumps in meth arrests in the past three years, according to a survey released in July 2005 by the National Association of Counties. But meth isn’t just a hard drug; it’s also an environmental hazard. 
 
Illicit drug makers can cook small batches of meth anywhere they can plug in a stove, microwave, or electric skillet (heat is not required, but speeds the manufacture). The ingredients include common cold medicines, ammonia fertilizer, and muriatic acid. Cooking generates a variety of noxious solvents and gases, such as hydrogen chloride, phosphine, and meth itself. According to an 8 August 2005 Newsweek article, for each pound of meth produced, five pounds of toxic waste are left behind. 
 
Police and firemen report breathing problems and headaches when they bust meth labs, but no one has quantified the hazards they face. So John Martyny, an industrial hygienist at National Jewish Medical and Research Center in Denver, teamed up with law enforcement officials in Colorado. They set up controlled cooks in an abandoned motel (which was later razed) and measured the resulting pollutants. 
 
In the unpublished studies, phosphine gas reached 2.9 parts per million (ppm), three times the occupational short-term exposure limit. Phosphine causes headache, pulmonary edema, and death. Martyny says cook fatalities are probably linked to this chemical. Hydrogen chloride fumes reached 155 ppm, more than three times the level considered by the National Institute for Occupational Safety and Health to be “immediately dangerous to life or health.” Hydrogen chloride causes respiratory tract damage. Ammonia, which causes lung edema, also soared to three times the “immediately dangerous to life or health” level. 
 
Anyone who is present during cooks is exposed to these and likely other toxicants; a third of all meth busts find children present. “The health costs to children may not be identified for years to come,” says Martyny, who predicts long-term respiratory and neurological problems. 
 
More research is needed to determine the best ways to clean up meth labs. Meth becomes airborne during production and settles on surfaces at up to 16,000 micrograms per 100 square centimeters (μg/100 cm2). Even six months after a staged cook, Martyny found meth levels of 300 μg/100 cm2 on surfaces. Carpets trap meth and other pollutants, yet vacuuming dra-meth levels. So Martyny recommends discarding carpets. 
 
Further, after grinding contaminated wallboard in separate unpublished studies, Stephen Lee, who supervises the Emergency Response Team at the Minnesota Pollution Control Agency in St. Paul, learned that washing walls removes less than 10% of the total meth. The rest is trapped deeper. Whether it bleeds back out to the surface and poses an exposure risk is unknown. Lee is evaluating whether a covering of oil-based paint seals meth within wallboard. 
 
Few states have guidelines for cleaning up meth labs. “As more states deal with remediation of meth properties, they turn to us,” says Carolyn Comeau, manager of the Clandestine Drug Lab Program at the Washington State Department of Health. Washington requires remediation by contractors certified by the state to decontaminate meth labs, which are often found in low-income rental properties. The state also requires that surface meth be at or below 0.1 μg/100 cm2 before new residents can move in. Scientific evidence like Martyny’s and Lee’s should yield more effective guidelines, says Comeau. 
 
Lee adds that a health-based standard for meth residues on building surfaces is needed to determine which properties need remediation and when a property has been adequately cleaned. All three experts support national remediation standards like those proposed in the Methamphetamine Remediation Research Act of 2005, which would establish a federal research program at the Environmental Protection Agency to study the environmental and health effects of meth labs and coordinate cleanup efforts. The bill has 55 cosponsors, and floor passage in the House is expected later this year.


INTRODUCTION
In the past few years, the insulin-like growth factor 1 receptor (IGF-1R) has emerged as a receptor tyrosine kinase (RTK) with important roles in cancer biology. The physiological responses to IGF-1R tyrosine kinase activation are diverse and include differentiation, proliferation, protection from apoptosis, cellular transformation, and cancer progression [1][2][3] The IGF-1R is a tetrameric receptor tyrosine kinase consisting of two ligand-binding extracellular a-subunits and two b-subunits composing a transmembrane domain, an intracellular tyrosine kinase domain and a C-terminal domain [4]. Ligand-receptor interaction results in phosphorylation of tyrosine residues in the tyrosine kinase (TK) domain (spanning from amino acid 973-1229) of the b-subunit. The crystal structure of the inactive and phosphorylated kinase domain has provided a molecular model of the IGF-1R catalytic activity [5]. In unstimulated state, the activation loop, containing the critical tyrosine (Y) residues 1131, 1135 and 1136, behaves as a pseudosubstrate that blocks the active site. Upon ligand binding the three tyrosines of the activation loop are transphosphorylated by the dimeric subunit partner. Phosphorylation of Y1135 and Y1131 destabilizes the auto-inhibitory conformation of the activation loop, whereas phosphorylation of Y1136 stabilizes the catalytically optimized conformation [5], allowing substrate and ATP access. The phosphorylated tyrosine residues serve as docking sites for other signaling molecules such as insulin receptor substrate 1-4 (IRS-1-4) and Shc, leading to the subsequent activation of the phosphatidyl inositol-3 kinase (PI3K), the mitogen-activated protein kinase (MAPK), and the 14-3-3 pathways [1,4,6,7].
Recent data has shown that IGF-1R is a substrate for ubiquitination, however, the role is unclear [8][9][10][11].Two E3 ligases, Mdm2 [8] and Nedd 4 [9], have been demonstrated to be involved in mediating the covalent attachment of ubiquitin moieties to lysine residues in IGF-1R. In Mdm2-mediated ubiquitination, barrestin function as a molecular scaffold in bridging the ligase to the receptor [12]. Similarly, Nedd4-mediated IGF-1R ubiquitination requires Grb10 to function as an adapter protein [9]. However, in spite of identification of these ligases involved, the understanding of the functional consequences and target residues are still limited.
In general, activated receptors must be cleared from the cell surface in order to desensitize the cell to mitogenic signals [13][14][15], and numerous studies have suggested a role for ligand-induced receptor internalization in the consequent degradation/desensitization of activated receptors [16]. There are several endocytic pathways that can mediate internalization of cell surface receptors, some of which are dependent on receptor ubiquitination [17,18]. The final step of receptor life cycle is degradation, which occurs either in lysosomes or in proteasomes or in both. Degradation through the proteasomal pathway requires that the receptor has undergone ubiquitination, however ubiquitinated receptors can also be degraded by lysosomes.
The fact that IGF-1R is ubiquitinated makes it as a possible substrate for proteasomal degradation. However, several studies have demonstrated that degradation of epidermal growth factor receptor (EGFR), being the most investigated RTK in this respect, is mediated by lysosomal proteases [13,[19][20][21]. The pathway through which IGF-1R is degraded is still an issue of debate. Evidence for involvement of the proteasomal pathway are mainly based on observations that the degradation of the IGF-1R can be blocked by the proteasome inhibitor MG132 [9,22]. However, it has recently been revealed that MG132 is not a specific inhibitor of proteasomal proteases and may also block the lysosomal pathway [23,24]. Accordingly, the degradation pathway responsible for downregulation of IGF-1R is still unclear.
Using different mutated constructs we aimed to identify functional sites and domains of IGF-1R necessary for receptor ubiquitination and to address whether ubiquitination is involved in control of signaling and degradation.

Functional sites and domains of IGF-1R
The b-subunit of the IGF-I receptor spans the membrane and contains the TK domain, responsible for the overall kinase activity of the receptor (Fig. 1A). The lysine K1003 serves as ATP-binding site and an IGF-1R construct with a point mutation at this site (K1003R) cannot be autophosphorylated [25]. The tyrosine Y1136 is located in the activation loop and is important for stabilization of kinase activity [5]. An IGF-1R construct with a point mutation at this site (Y1136F) exhibits a decreased kinase activity [26]. A phosphorylated Y950 is important for binding of IRS-1 and Shc, and therefore is necessary for normal signaling (Fig. 1A). Consequently, an IGF-1R construct with a single mutation at Y950 site (Y950F) leads to impaired signaling [27]. The C-terminal domain is also involved in signaling [28,29]. A Ctail truncated IGF-IR (D1245, missing the last 92 amino acids) (Fig. 1A) exhibits impaired signaling [28,29], whereas the Y950F+D1245 construct beside lacking the C-terminal domain also has impaired IRS-1/Shc binding (Fig. 1A). In order to study these constructs in cell systems we used R-cells (IGF-1R knockout) stably transfected with wild type IGF-1R (here referred to as wt), Y1136F, D1245 and Y950F+D1245 as well as transiently transfected with K1003R. All constructs are of human origin.
The expression level of the above IGF-1R variants under basal conditions is demonstrated in Fig. 1B. As shown, D1245 and Y950F+D1245 cells exhibit the strongest receptor expression.

Phosphorylation is necessary for ubiquitination of IGF-1R
Upon ligand (IGF-1) stimulation the IGF-1R is rapidly autophosphorylated and, as recently demonstrated, ubiquitinated [8,9]. However, the relationship between these two modifications has not been studied in detail. To investigate this issue, wt IGF-1R and K1003R cells were serum depleted for 24 h and then stimulated with IGF-1 for the indicated times (Fig. 2). IGF-1R was immunoprecipitated from cell lysates and analyzed by western blotting for phosphotyrosine and ubiquitin modifications. Phosphorylation of wild type IGF-1R was detectable 1 min after ligand exposure, peaking at 5 min but still detectable at later time points (10 and 20 min) ( Fig. 2A). The ubiquitination of the receptor which starts simultaneously as phosphorylation, is visualized as a high-molecular smear.90 kDa, peaking at 5 min (Fig 2A). The graphs show the quantified signals of receptor phosphorylation and ubiquitination based on 3 separate experiments. In the kinase inactive IGF-1R cells (K1003R) where the receptor phosphorylation is abolished no ubiquitination was observed, indicating that IGF-1R kinase activity is required for IGF-1-induced ubiquitination.

C-terminal domain is required for IGF-1R ubiquitination
Next we sought to investigate the potential requirement of specific sites/domains of the IGF-1R for receptor ubiquitination. In this respect, we used cells stably transfected with the 4 aforementioned IGF-1R mutants (Fig. 1). As shown in Fig. 3, Y1136F cells (with impaired IGF-1R kinase activity due to a point mutation at Y1136 site in the activation loop) is phosphorylated and ubiquitinated shortly after ligand stimulation, however the phosphorylation and ubiquitination patterns are transient when compared with wild type ( Fig. 2A). Both phosphorylation and ubiquitination of the receptor were detectable exclusively after 1 min exposure to IGF-1, however not after longer stimulation times (3-20 min). Cells expressing Y950F receptors (with impaired signaling due to reduced binding of Shc and IRS-1 to the receptor) displayed phosphorylation and ubiquitination with similar kinetics as the wild type IGF-1R (cf. Fig. 2A), although the ubiquitination signals persisted longer in Y950F cells (Fig. 3). Interestingly, whereas the C-tail truncated IGF-1Rs in D1245 and Y950F-D1245 cells are fully phosphorylated (compared to the wild type receptor), the ubiquitination capacity is completely abolished (Fig. 3). This suggests that the C-terminal domain is critical for IGF-1 mediated ubiquitination.

IGF-1R ubiquitination is important for ERK activation
Since we now have identified an IGF-1R construct with deficient ubiquitination capacity we sought to investigate whether ubiquitination influences the signaling responses mediated by IGF-1R. We stimulated serum starved wt, K1003R, Y1136F and D1245 cells with IGF-1 for different time points (0-20 min). Phosphor- ylation of ERK1/2 was assessed as a measure of MAPK activation and phosphorylation of Akt as a measure of PI3K activation. The levels of expression of phospho-ERK1/2 and phospho-(S473) Akt were investigated by immunoblot analysis (Fig. 4). Akt phosphorylation induced by wild type IGF-1R was seen after 1 min of IGF-1 stimulation, peaked at 3 min and was maintained until the final time point. IGF-1 induced phosphorylation of ERK1/2 became detectable at 3 min and reached a maximum at 10 min after which the level declined (Fig. 4). As expected K1003R cells showed neither Akt nor ERK phosphorylation. Consistent with previous report [30] Y1136F transfected cells did not exhibit any Akt activation, whereas ERK1/2 activation resembled that of wild type IGF-1R (Fig. 4). Intriguingly, IGF-1 stimulation of Cterminal truncated IGF-1R in D1245 cells activated Akt but not ERKs. This suggests that IGF-1R ubiquitination, shown for wt and Y1136F in Fig. 2 and 3, is important for signaling of the MAPK pathway. Consequently, the transient ubiquitination (detectable only at 1 min of ligand stimulation) observed for the  Y1136F mutant seems to be sufficient to activate ERKs. On the other hand, it is evident that activation of the PI3K/Akt signaling pathway requires a higher IGF-1R kinase activity.

Ubiquitination status correlates with pathway of IGF-1R degradation
We investigated degradation of the different IGF-1R constructs using cyclohexamide (CHX) to block de novo protein synthesis as described elsewhere [31][32][33]. Cells, grown under basal conditions, were exposed to CHX for 6 or 12 h. To find out whether the receptors were degraded by lysosomes and/or proteasomes, lysosomal and proteasomal inhibitors were utilized. Cloroquine is a lysosomotropic weak base, which diffuses across membranes in a concentration-dependent manner. It rapidly becomes protonated thereby neutralizing the acidic environment of endocytic vesicles [34]. Whereas, epoxomicin specifically targets the proteasomes by inhibiting primarily the chymotrypsin-like activity [24]. In contrast to peptide aldehyde proteasome inhibitors like MG132, epoxomicin does not inhibit non-proteasomal proteases such as trypsin, chymotrypsin, papain, calpain, and cathepsin B at concentrations of up to 50 mM [24]. In addition, epoxomicin is a more potent inhibitor of the chymotrypsin-like activity than lactacystin and the peptide vinyl sulfone NLVS [24].
Wt, K1003R and D1245 cells were pre-treated with epoxomicin or chloroquine before treatment with CHX and the levels of IGF-1R expression were analyzed by western blotting (Fig. 5A) and quantified by densitometry (Fig. 5B). As seen in Fig 5, in the absence of inhibitor wild type IGF-1R was reduced by approximately 50% after 12 h. The lysosome inhibitor (LyI) completely prevented the degradation, while the proteasome inhibitor (PI) had a moderate, although statistically significant (P,0.05), stabilizing effect on IGF-1R. Fig. 5 also shows that the ATPM receptor, being deficient in both ubiquitination and phosphorylation, is not degraded at all during the 6 or 12 h experiments. These data suggest that phosphorylation is necessary for degradation and moreover indicate that the lysosomes represent the main pathway by which the wild type IGF-1R is degraded. Nevertheless, the fact that IGF-1R degradation is somewhat delayed (approximately with 20%) in the presence of PI (Fig. 5B) indicates that the proteasomal activity facilitates IGF-1R degradation. We tried to address whether this effect is directly due to involvement of proteasomes in IGF-1R degradation or is mediated through other mechanisms. It has been suggested for some receptors (e.g. interleukin 2 receptor and EGFR) that ubiquitination is important for endosomal sorting where ubiquitin seems to be required to prevent internalized receptors from recycling by shunting them into a pathway that results in lysosomal degradation [35][36][37]. Another explanation could be that the free pool of ubiquitin dramatically decreases after proteasome inhibitor treatment leading to altered ubiquitination patterns of the receptor, followed by altered internalization and lysosomal degradation. Therefore, we investigated degradation of IGF-1R in D1245 cells (Cterminal truncated IGF-1R), which is phosphorylated but defective in ubiquitination. The C-terminal truncated IGF-1R is entirely protected from degradation by the lysosome inhibitor, whereas proteasome inhibitor had no protecting effect on it (Fig. 5B). Taken together, this suggests that the delay in degradation of wild type IGF-1R caused by proteasome inhibition might be a direct effect of receptor ubiquitination and not due to indirect effects such as altered internalization caused by lack of free ubiquitin Unexpectedly, we observed that the mutant receptors in Y1136F and Y950F cells, which both exhibited IGF-1R ubiquitination (Fig. 3), are mainly degraded through proteasomes (Fig. 6). Untreated Y1136F is degraded by 70% after 12 h. Lysosome inhibitor decreased this degradation by 40% while the proteasome inhibitor abolished it totally. The same pattern was seen in Y950F cells. In Y950F-D1245 cells, with truncated C-tail and impaired IRS-1/Shc binding, the receptor showed essentially similar responses as in D1245 cells ( Fig. 5 and 6).

DISCUSSION
In this study we sought to shed light on regulation of and role of IGF-1R ubiquitination. The results presented here show that phosphorylation of the receptor is necessary for its ubiquitination.
Furthermore, we can state that the C-terminal domain of the receptor is needed in this context. In wild type IGF-1R the profile of ubiquitination matches its phosphorylation status. However, Ctail truncated IGF-1R cannot be ubiquitinated in spite of its normal kinase activity. Since, C-terminal truncation of IGF-1R inhibits receptor ubiquitination, one could speculate that the lysine(s) required for ubiquitination are located in the C-tail. However, out of the 29 lysine residues in the b-subunit of the IGF-1R only three are in the C-tail domain. Although these three lysines might function as ubiquitin acceptors, another possibility is that the C-terminal domain functions as an E3 ligase binding site. Further studies are, however, required to understand the distinct mechanism by which C-terminal truncation inhibits ubiquitination of IGF-1R. Importantly, when ubiquitination of IGF-1R is prevented by C-tail truncation the receptor is degraded explicitly through the lysosomes, suggesting a role of IGF-1 induced ubiquitination in proteasomal degradation of the receptor.
Intriguingly, we observed that the IGF-1R mutant Y1136F is mainly degraded via the proteasomes. Since this mutant did not exhibit any Akt phosphorylation, but intact phosphorylation of ERK1/2, it is possible that the PI3K/Akt pathway has a positive regulatory influence on lysosomal degradation. A similar predominance of proteasomal degradation occurred in case of the Y950F mutant, which has an impaired IRS-1 binding [38,39]. Further support for a role of the PI3K/Akt signaling pathway in this context is contributed by our observations that all IGF-1R constructs exhibiting fully detectable Akt phosphorylation are mainly degraded by the lysosomes. Interestingly, accumulating data have emphasized a role of IGF-1 activated Akt in phosphorylation and nuclear localization of Mdm2 [40][41][42]. These results could offer an explanation regarding the different pattern of IGF-1R degradation in the various mutants. Consistently, in mutant cell lines with impaired Akt activation (Y950F and Y1136F), Mdm2 is probably not phosphorylated with an increased cytoplasmic pool of Mdm2 as a consequence. Since Mdm2 is a ligase required for ubiquitination of IGF-1R [8], the raised levels of cytoplasmic Mdm2 would increase ubiquitination of IGF-1R followed by proteasomal degradation.
In summery we have identified a receptor domain critical for the IGF-1R ubiquitination and show that this post-modification is dependant of phosphorylation of the receptor. Furthermore, we show the co-existence of both proteasomal and lysosomal pathway for IGF-1R degradation, in which PI3K/Akt signaling may be important for the lysosomal pathway and ubiquitination for the proteasomal one. Also, IGF-1R activated MAPK/ERK signaling may be controlled by ubiquitination of the receptor.

Transient transfection
R-cells were seeded to 90% confluence in 10-cm dishes (Falcon) with plasmids using Lipofectamine 2000 (Life Technologies, Inc., Grand Island, NY), according to the manufacturer's instructions. 24 h after transfection cells were splited into 6 well plates and cultured for an additional 24 h in the presence of 0.6 mg/ml G418. During the last 24 h, cells were starved and then stimulated for indicated times with 50 ng/ml IGF-1. Cells were lyzed in lysis buffer (0.5% Triton-x-100, 0.5% Doc Deoxycholic acid,150 mM NaCl, 20 mM Tris pH 7.5, 10 mM EDTA, 30 mM sodium pyrophosphate, 10% glycerol, 1 mM phenylmethylsulfonyl fluo-ride, protease inhibitor cocktail tablet (Roche, Mannheim, Germany), phosphatase inhibitor 1 and 2, and 10 mM N-Ethylmaleimide). Protein extracts were prepared for immunoprecipitation or western blot analyses.

SDS/PAGE and western blot analysis
Cell lysate were distracted as described above. Protein samples were dissolved in a sample buffer containing 0.0625 M Tris?HCl (pH 6.8), 20% glycerol, 2% SDS, bromophenol blue, and 2bmercaptoetanol. Samples corresponding to 50-100 mg of cell protein were separated by 7.5% or 4-12% gradient sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE). Molecular weight markers (Bio-Rad) were run simultaneously. After SDS/PAGE the proteins were transferred onto nitrocellulose membranes (Hybond, Amersham, UK) and blotted with the indicated antibodies. This was followed by washes and incubation with a HRP conjugated secondary antibody (ImmunoPure antibody, Pierce), and detected with (Hyperfilm-ECL, Amersham, UK).

Immunoprecipitation
Cells were cultured to subconfluency in 6-cm plates. The cells were serum-depleted for 24 h, and then stimulated by IGF-1 (50 ng/ml) at indicated time points. For determination of IGF-1R phosphorylation and ubiquitination, cell lysates were extracted with lysis buffer as described above. Twenty ml of protein G Sepharose and 1 mg of antibody were added to 1 mg of protein material. After overnight incubation at 4uC on a rocker platform, the immunoprecipitates were collected by centrifugation in a microcentrifuge at 2,500 rpm for 2 min. The supernatant was discarded, whereupon the pellet was washed 2 times with lysis buffer and 1 time with PBS and then dissolved in a sample buffer for SDS/PAGE and further was analyzed by western blotting.

Degradation assay
Protein degradation was assessed by cycloheximide-chase assay as to previously described [31,32]. The effect of lysosome inhibitor (LyI), cloroquine and proteasome inhibitor (PI), epoxomicin on the stability of the entire IGF-1R pool was examined by immunoblot analysis at 6-and 12 h after treatment with cycloheximide. Cell lines with wild type and different IGF-1R mutants were grown on plates and the levels of IGF-1R were studied with and without PI and LyI. The experiment was preformed in complete culture medium in order to follow receptor downregulation under physiological conditions. The protein synthesis of the cells was subsequently inhibited with cycloheximide (CHX, 50 mg/ml) that was maintained during the whole experiment. In cases where proteasomes were inhibited, epoxomicin was added to a final concentration of 100 nM, 6 h [24,44] prior to addition of cycloheximide. Lysosomes were inhibited by adding chloroquine to a final concentration of 50 mM 30 min [45,46] before addition of cycloheximide and were present throughout the experiment.